Search Within

Margaret Kathleen Callahan

  1. "Computational Oncology Service"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (4)
Groups
  1. Computational Oncology Service (9)
  2. Department of Medicine (9)
  3. Epidemiology and Biostatistics (9)
  4. GSK Faculty (9)
  5. Melanoma and Immunotherapeutics Service (9)
  6. Solid Tumor Oncology Division (9)

More Groups

People
  1. Jedd Wolchok (6)
  2. Nikolaus Schultz (6)
  3. Alexander Shoushtari (5)
  4. Michael Postow (5)
  5. David Solit (4)
  6. Francisco Sanchez Vega (4)

More People

Years
  1. 2022 (2)
  2. 2021 (1)
  3. 2019 (1)
  4. 2018 (3)
  5. 2017 (1)
  6. 2016 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (1)
  3. Cancer Cell (1)
  4. Clinical Cancer Research (1)
  5. JCO Precision Oncology (1)
  6. Nature (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (1)
  3. Cell Press (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Fundamental immune–oncogenicity trade-offs define driver mutation fitness
    Journal Article

    Hoyos, D.; Zappasodi, R.; Schulze, I.; Sethna, Z.; de Andrade, K. C.; Bajorin, D. F.; Bandlamudi, C.; Callahan, M. K.; Funt, S. A.; Hadrup, S. R.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
    Meeting Abstract

    Shoushtari, A. N.; Sanchez-Vega, F.; Kantheti, H.; Callahan, M. K.; Postow, M. A.; Barker, C. A.; Chatila, W. K.; Jonsson, P.; Ariyan, C. E.; Brady, M. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Shoushtari, A. N.; Armenia, J.; Arora, A.; Rojas-Zamalloa, J.; Warner, A. B.; Derr, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Coit, D. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma
    Meeting Abstract

    Gottesdiener, L. S.; Gormally, M.; Armenia, J.; El-Jalby, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Wolchok, J. D.; Chapman, P. B.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save